Gene-Modified HIV-Protected Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma
NCT ID: NCT02378922
Last Updated: 2018-12-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE1
INTERVENTIONAL
2016-06-22
2019-06-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
I. To assess the safety and feasibility of infusing gene-modified, HIV-protected hematopoietic stem/progenitor cells (HSPC) after high-dose chemotherapy for treatment of acquired immune deficiency syndrome (AIDS)-related lymphoma.
II. To observe the change in gene-modified cell levels before and after antiviral treatment interruption.
SECONDARY OBJECTIVES:
I. To evaluate the molecular and clonal composition of gene-modified cells after hematopoietic cell transplant (HCT).
II. To describe time to disease progression, progression-free survival, treatment-related mortality, time to neutrophil and platelet recovery, and incidence of infections.
TERTIARY OBJECTIVES:
I. To evaluate the effect of procedure on HIV-specific immune reconstitution.
II. To observe the effect of HIV infection on the presence of gene-marked cells as determined by deoxyribonucleic (DNA) polymerase chain reaction (PCR).
OUTLINE:
CONDITIONING: Patients undergo high-dose chemotherapy or chemoradiotherapy according to institutional guidelines.
STEM CELL INFUSION: Patients undergo hematopoietic stem cell transplant with LVsh5/C46 (Cal-1) transduced autologous CD34+ hematopoietic stem/progenitor cells (HSPC) on day 0.
Note: Patients continue to receive highly active antiretroviral therapy (HAART) throughout treatment, with a 7-day break for apheresis. Patients may be eligible for a structured treatment interruption of up to 12 weeks after autologous hematopoietic stem cell transplant with gene-modified cells.
After completion of study treatment, patients are followed up periodically for 2 years, every 6 months for 3 years, and then annually for 15 years post-HCT.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment (gene-modified stem cells)
CONDITIONING: Patients undergo high-dose chemotherapy or chemoradiotherapy according to institutional guidelines.
STEM CELL INFUSION: Patients undergo hematopoietic stem cell transplant on day 0.
Note: Patients continue to receive HAART throughout treatment, with a 7-day break for apheresis. Patients may be eligible for a structured treatment interruption of up to 12 weeks after autologous hematopoietic stem cell transplant with gene-modified cells.
Gene-Modified HIV-Protected Hematopoietic Stem Cells
Receive LVsh5/C46 (Cal-1) transduced CD34+ HSPC IV
Laboratory Biomarker Analysis
Correlative studies
Transplant Conditioning
Undergo high-dose chemotherapy or chemoradiotherapy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Gene-Modified HIV-Protected Hematopoietic Stem Cells
Receive LVsh5/C46 (Cal-1) transduced CD34+ HSPC IV
Laboratory Biomarker Analysis
Correlative studies
Transplant Conditioning
Undergo high-dose chemotherapy or chemoradiotherapy
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Stable, continuous antiretroviral treatment for at least three months before enrollment, defined as a multi-drug regimen (excluding azidothymidine \[AZT\])
* HIV plasma viral load \< 50 copies/ml
* Non-Hodgkin or Hodgkin lymphoma without active central nervous system (CNS) involvement associated with poor prognosis with medical therapy alone or for which autologous peripheral blood stem cell (PBSC) transplant is indicated:
* Hodgkin's lymphoma beyond first remission or first partial remission or induction failure with subsequent response to salvage therapy
* Non-Hodgkin's lymphoma beyond first remission or first partial remission or induction failure with subsequent response to salvage therapy
* Chemotherapy responsive disease
* Karnofsky performance score \>= 70%
* Subjects must agree to use effective contraception from enrollment through completion of the study
* Female subjects: if of child bearing potential, must have negative serum or urine pregnancy test within 7 days of enrollment
* Subjects must be on a prophylactic regimen for pneumocystis carinii pneumonia, or agree to begin such treatment, if CD4+ cell counts are observed to be =\< 200/ul in peripheral blood
* Ability to understand and the willingness to sign a written informed consent document
Exclusion Criteria
* Liver disease: alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than 3 times the upper limits of normal, unless determined to be a result of the primary hematologic malignancy
* Serum bilirubin greater than 3 times the upper limit of normal, unless attributed to Gilbert's syndrome
* Pulmonary disease: forced vital capacity (FVC) \< 60% predicted
* Pulmonary disease: forced expiratory volume in 1 second (FEV1) \< 60% predicted
* Pulmonary disease: diffusion capacity of the lung for carbon monoxide (DLCO) parameters \< 60% predicted (corrected for hemoglobin)
* Cardiac insufficiency: left ventricular ejection fraction (LVEF) \< 50% or coronary artery disease requiring treatment
* Active infection requiring systemic antibiotic therapy with antibacterial, antifungal, or antiviral agents (excluding HIV)
* Hepatitis B surface antigen positive
* Hepatitis C virus (HCV) antibody positive and detectable HCV quantitative ribonucleic acid (RNA) with clinical evidence of cirrhosis
* Requiring active treatment for Toxoplasma gondii
* Planned radiation therapy after transplant
* Malignancy other than lymphoma, unless (1) in complete remission and more than 5 years from last treatment, or (2) cervical/anal squamous cell carcinoma in situ or (3) superficial basal cell and squamous cell cancers of the skin
* History of HIV-associated encephalopathy; dementia of any kind; seizures in the past 12 months; any perceived inability to directly provide informed consent (Note: Consent may not be obtained by means of a legal guardian)
* A medical history of noncompliance with HAART or medical therapy
* Any concurrent or past medical condition that, in the opinion of the Investigator, would exclude the subject from participation or any psychosocial conditions that would hinder study compliance or follow-up, at the discretion of the Investigator
* Receipt of a vaccine for HIV-1 or any prior gene modified cell product, at any time
* Known hypersensitivity to any of the products used in the trial-G-CSF (Neupogen), plerixafor, or any planned components of conditioning regimens
* Pregnant or nursing women
18 Years
66 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Fred Hutchinson Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hans-Peter Kiem
Role: PRINCIPAL_INVESTIGATOR
Fred Hutch/University of Washington Cancer Consortium
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2015-00149
Identifier Type: REGISTRY
Identifier Source: secondary_id
9183
Identifier Type: OTHER
Identifier Source: secondary_id
9183
Identifier Type: -
Identifier Source: org_study_id